TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.73 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $1.73, a 84.47% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.60.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $23.54.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $11.14.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $9.45, a 104.55% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.62.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $11.67, a 2.67% decline from fiscal 2018.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $11.99, a 4.62% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.73 10-Q · filed 2026-08-14 | $2.51 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $2.60 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $9.45 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $23.54 10-Q · filed 2025-11-13 | $11.20 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $11.14 10-Q · filed 2026-08-14 | $11.14 10-Q · filed 2025-08-14 | ||
| 2024-12-31 | $4.62 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $4.62 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $4.62 10-Q · filed 2025-08-14 | |||
| 2020-09-30 | $11.11 10-Q · filed 2020-11-09 | $10.70 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $10.23 10-Q · filed 2020-08-10 | $10.53 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $10.59 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $11.67 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $15.29 10-Q · filed 2020-11-09 | $11.35 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $13.07 10-Q · filed 2020-08-10 | $11.28 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $10.83 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $11.99 10-K · filed 2020-02-27 | |||
| 2018-09-30 | $14.51 10-Q · filed 2019-11-05 | $11.25 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $10.49 10-Q · filed 2019-08-07 | $10.51 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $10.43 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $11.46 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $10.00 10-Q · filed 2018-11-06 | $11.61 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $13.53 10-Q · filed 2018-08-07 | $12.41 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $12.27 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $4.28 10-K · filed 2019-03-12 | |||
| 2016-09-30 | $3.92 10-Q · filed 2017-11-02 | $3.81 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | $3.55 10-Q · filed 2017-08-03 | $3.80 10-Q · filed 2017-08-03 | ||
| 2015-12-31 | $7.17 10-K · filed 2018-03-15 | |||
| 2014-12-31 | $7.09 10-K · filed 2015-03-27 | |||
| 2014-03-31 | $6.88 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |